All In Biotech

Drug Trial Radar · NCT02828020

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Last checked: Nov 19, 2026Latest source record: Jan 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,672 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,672

Actual

Start

Jul 22, 2016

Primary completion

Dec 13, 2017

Study completion Dec 14, 2017

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Jul 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.

Conditions

  • Migraine, With or Without Aura

Interventions

  • UbrogepantDrug

    50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

  • Placebo-matching UbrogepantDrug

    Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Pain Freedom at 2 Hours After Initial DoseTime frame: Baseline (Predose) to 2 hours after initial dose
  2. Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial DoseTime frame: Baseline (Predose) to 2 hours after initial dose

Locations

90 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Advantage, Inc./Desert Clinical Research, LLC.

    Mesa, Arizona

  • Xenoscience, Inc.

    Phoenix, Arizona

  • Clinical Research Advantage, Inc./Orange Grove Family Practice

    Tucson, Arizona

  • Principals Research Group, Inc.

    Hot Springs, Arkansas

  • KLR Business Group, Inc. dba Arkansas Clinical Research

    Little Rock, Arkansas

  • The Research Center of Southern California, LLC

    Carlsbad, California

  • Med Center

    Carmichael, California

  • T. Joseph Raoof MD, Inc./Encino Research Center

    Encino, California

  • Neurology Center of North Orange County

    Fullerton, California

  • Behavioral Research Specialists, LLC

    Glendale, California

  • Prime Care Clinical Research

    Laguna Hills, California

  • Collaborative Neuroscience Network, LLC.

    Long Beach, California

  • Synergy San Diego

    National City, California

  • Newport Beach Clinical Research Associates, Inc.

    Newport Beach, California

  • North County Clinical Research

    Oceanside, California

  • Medical Center for Clinical Research

    San Diego, California

  • CA Medical Clinic for Headache

    Santa Monica, California

  • Southern California Research LLC

    Simi Valley, California

  • Encompass Clinical Research

    Spring Valley, California

  • Alpine Clinical Research Center, Inc.

    Boulder, Colorado

  • Colorado Springs Neurological Associates

    Colorado Springs, Colorado

  • Delta Waves, Inc

    Colorado Springs, Colorado

  • Denver Neurological Research

    Denver, Colorado

  • Associated Neurologists, P.C.

    Danbury, Connecticut

  • Associated Neurolgists of Southern Connecticut, PC

    Fairfield, Connecticut

  • Sarkis Clinical Trials

    Gainesville, Florida

  • CPI MD Clinical

    Hallandale, Florida

  • Infinity Clinical Research, LLC

    Hollywood, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • Palm Beach Neurological Center/Advanced Research Consultants, Inc.

    Palm Beach Gardens, Florida

  • Meridien Research

    Spring Hill, Florida

  • University of South Florida

    Tampa, Florida

  • Meridien Research

    Tampa, Florida

  • Neurology Research Institute

    West Palm Beach, Florida

  • Midtown Neurology

    Atlanta, Georgia

  • Columbus Regional Research Institute

    Columbus, Georgia

  • Clinical Research Atlanta

    Stockbridge, Georgia

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Deaconess Clinic, Medical Office Building 1 Research Institute

    Newburgh, Indiana

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.